孟鲁司特钠口服联合布地奈德雾化吸入对咳嗽变异性哮喘患者肺功能及相关血清免疫指标水平的影响

目的:探讨孟鲁司特钠口服联合布地奈德雾化吸入对咳嗽变异性哮喘患者的肺功能及相关血清免疫指标水平的影响。方法:选取2016—2017年焦作市中医院收治的咳嗽变异性哮喘患者78例作为研究对象。按数字1~78进行编号,单号为观察组,双号为对照组,每组39例。对照组患者给予布地奈德气雾剂雾化吸入,观察组患者在对照组基础上联合应用孟鲁司特钠口服,两组患者均治疗8周。比较两组患者治疗前后肺功能指标[第一秒用力呼气量(FEV_1)、用力肺活量(FVC)]、血清免疫指标[血清免疫球蛋白E(IgE)、肿瘤坏死因子α(TNF-α)和白细胞介素4(IL-4)]水平变化情况及不良反应发生情况。结果:治疗后,两组患者F...

Full description

Saved in:
Bibliographic Details
Published in中国医院用药评价与分析 Vol. 17; no. 12; pp. 1614 - 1615
Main Author 郑雪玲;李文波;郝建伟
Format Journal Article
LanguageChinese
Published 焦作市中医院检验科,河南焦作,454000%焦作市中医院内科,河南焦作,454000 2017
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:目的:探讨孟鲁司特钠口服联合布地奈德雾化吸入对咳嗽变异性哮喘患者的肺功能及相关血清免疫指标水平的影响。方法:选取2016—2017年焦作市中医院收治的咳嗽变异性哮喘患者78例作为研究对象。按数字1~78进行编号,单号为观察组,双号为对照组,每组39例。对照组患者给予布地奈德气雾剂雾化吸入,观察组患者在对照组基础上联合应用孟鲁司特钠口服,两组患者均治疗8周。比较两组患者治疗前后肺功能指标[第一秒用力呼气量(FEV_1)、用力肺活量(FVC)]、血清免疫指标[血清免疫球蛋白E(IgE)、肿瘤坏死因子α(TNF-α)和白细胞介素4(IL-4)]水平变化情况及不良反应发生情况。结果:治疗后,两组患者FEV_1、FVC水平较治疗前明显升高,且观察组患者改善情况明显优于对照组,差异均有统计学意义(P〉0.05);治疗后,两组患者IgE、IL-4和TNF-α水平较治疗前明显改善,且观察组患者改善程度明显优于对照组,差异均有统计学意义(P〈0.05)。两组患者不良反应发生率的差异无统计学意义(P〉0.05)。结论:雾化吸入布地奈德气雾剂联合孟鲁司特钠口服治疗咳嗽变异性哮喘的效果较好,可改善患者肺功能,缓解炎症反应,且安全性较高。
Bibliography:OBJECTIVE: To probe into the effects of montelukast sodium combined with budesonide for aerosol inhalation on pulmonary function and serum Immune indices of patients with cough variant asthma. METHODS: 78 patients with cough variant asthma admitted into Jiaozuo Traditional Chinese Medicine Hospital during 2016-2017 were selected and numbered to be 1-78, patients with odd numbers were classified as observation group, even numbers were control group, with 39 cases in each group. The control group was treated with budesonide aerosol for inhalation, while the observation group was given montelukast sodium combined with budesonide aerosol. After an 8-week treatment, two groups were compared before and after treatment in terms of pulmonary function .[ ( forced expiratory volume in first second (FEV1 ) and forced vital capacity (FVC)] and sermn Immune indices including serum immune globulin E (IgE), tumor necrosis factor ct (TNF-o~) and interleukin 4 (IL-4), the incidences of adverse drug reactions of two groups wer
ISSN:1672-2124
DOI:10.14009/j.issn.1672-2124.2017.12.008